Statistical methodology for the comparative assessment of quality attributes in drug development - Scientific guideline
Table of contents
The reflection paper provides current regulatory considerations regarding statistical aspects for the comparative assessment of quality attributes in the settings of pre- and post-manufacturing change, biosimilar development as well as generics development. It raises open issues from a methodological perspective addressing questions related to comparison objectives, sampling strategies, sources of variability, acceptance ranges and statistical analysis approaches to conclude on the similarity of two drug products based on quality attribute data. A main objective of the reflection paper is to establish a framework and a common language to facilitate future discussion among stakeholders and to invite comments in relation to the issues raised.
Keywords: Statistical methodology, comparative assessment, quality attributes, drug development, manufacturing changes, biosimilars, generics, dissolution, inferential statistical methods, similarity assessment
-
List item
Implementation of comments received on 'Draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development' (PDF/101.85 KB)
First published: 27/07/2021
EMA/CHMP/310801/2021 -
List item
Draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development (PDF/272.25 KB)
Draft: consultation closed
First published: 31/03/2017
Last updated: 31/03/2017
Consultation dates: 01/04/2017 to 31/03/2018
EMA/CHMP/138502/2017 -
List item
Draft concept paper on the need for a reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development (PDF/96.67 KB)
Draft: consultation closed
First published: 28/06/2013
Last updated: 16/01/2014
Consultation dates: 28/06/2013 to 30/09/2013
EMA/CHMP/297149/2013 Rev. 1